News | April 30, 2007

CyberHeart to Develop Noninvasive Cardiac Ablation Technique Using Accuray Robotic System

Accuray Inc., a manufacturer of radiosurgery devices, has announced it has entered into an agreement with CyberHeart Inc. under which CyberHeart will use Accuray’s technology to develop a noninvasive method for performing cardiac ablation, which may eventually have applications in the treatment of atrial fibrillation.

Currently cardiac ablation is done during open-heart surgery or as a catheter based procedure in which a catheter is inserted into a blood vessel up to the heart and radiofrequency energy is delivered. Cardiac ablation is most often used to create a lesion that that interferes with abnormal cardiac conduction, with the objective of treating cardiac arrhythmias.

CyberHeart is exploring the use of Accuray’s CyberKnife Robotic Radiosurgery System to generate these lesions noninvasively. The CyberKnife System’s intelligent robotics, accuracy and unique tracking capabilities will be used to target the heart’s affected tissue and create an ablation lesion.

CyberHeart has received commitments for independent venture capital financing to fund technical and clinical research and development of a cardiac ablation system that incorporates Accuray’s technology. In the event CyberHeart is able to successfully develop and commercialize such a system, under Accuray’s agreement with CyberHeart, Accuray will be the sole supplier of radiosurgery equipment to CyberHeart and will also be entitled to receive specified payments based on usage of the CyberHeart system.

According to Accuray, the CyberKnife System represents the next generation of radiosurgery systems, combining continuous image-guidance technology with a compact linear accelerator that has the flexibility to move in three dimensions according to the treatment plan. This combination, which is referred to as intelligent robotics, extends the benefits of radiosurgery to the treatment of tumors anywhere in the body. The CyberKnife System autonomously tracks, detects and corrects for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation typically with sub-millimeter accuracy.

For more information visit www.accuray.com.

Related Content

Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Sponsored Content | Videos | Atrial Fibrillation| May 17, 2017
Hugh Calkins, M.D., FACC, FAHA, FHRS, director of cardiac arrhythmia services and professor of medicine at Johns Hopk
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
The Arctic Front Advance Cardiac CryoAblation Catheter treats atrial fibrillation with pulmonary vein isolation
News | Atrial Fibrillation| April 11, 2017
April 10, 2017 — Medtronic recently announced the first enrollments in the STOP Persistent AF clinical trial.
Overlay Init